Last update 31 May 2024

Capivasertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Capivasertib (JAN/USAN), Capivastertib, AZ12952302
+ [4]
Mechanism
Akt-1 inhibitors(Serine/threonine-protein kinase AKT inhibitors), Akt-2 inhibitors(Serine/threonine-protein kinase AKT2 inhibitors), Akt-3 inhibitors(Serine/threonine-protein kinase AKT3 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC21H25ClN6O2
InChIKeyJDUBGYFRJFOXQC-KRWDZBQOSA-N
CAS Registry1143532-39-1

External Link

KEGGWikiATCDrug Bank
D11371--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hormone receptor positive HER2 negative breast cancer
US
16 Nov 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ER-positive/HER2-negative Breast CancerNDA/BLA
EU
25 Apr 2024
Metastatic castration-resistant prostate cancerPhase 3
US
25 Mar 2022
Metastatic castration-resistant prostate cancerPhase 3
CN
25 Mar 2022
Metastatic castration-resistant prostate cancerPhase 3
JP
25 Mar 2022
Metastatic castration-resistant prostate cancerPhase 3
AU
25 Mar 2022
Metastatic castration-resistant prostate cancerPhase 3
BE
25 Mar 2022
Metastatic castration-resistant prostate cancerPhase 3
BR
25 Mar 2022
Metastatic castration-resistant prostate cancerPhase 3
CA
25 Mar 2022
Metastatic castration-resistant prostate cancerPhase 3
CL
25 Mar 2022
Metastatic castration-resistant prostate cancerPhase 3
CZ
25 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Hormone receptor positive HER2 negative breast cancer
HER2− defined as IHC 0, or 1+ or IHC2+/ISH-
708
ocyuzqauli(esifeqnrdh) = Diarrhea with C-F was generally manageable, and discontinuations due to diarrhea were low (2.0%; n=7/355) dhgcofoqwf (bitztfqwmx )
Positive
05 Dec 2023
Placebo + Fulvestrant
Phase 3
134
fqwcgqjbpj(shkkarhrjn) = obrsgrftmr gmmztyisuk (ydjtdfwjxc )
Positive
02 Dec 2023
Placebo + fulvestrant
fqwcgqjbpj(shkkarhrjn) = tsuhgmkapi gmmztyisuk (ydjtdfwjxc )
Phase 3
708
(PIK3CA/AKT1/PTEN-Altered Tumors)
mfavyhoksv(vtjgevjqah) = qdvtvwoloa xvkhuhknsa (fcxbqwdunu )
Positive
16 Nov 2023
placebo+fulvestrant
(PIK3CA/AKT1/PTEN-Altered Tumors)
mfavyhoksv(vtjgevjqah) = vfxhdodpkd xvkhuhknsa (fcxbqwdunu )
Phase 2
15
auojfgwkrv(didxrbzjqj) = tbhgwjgpwb yiajjdagde (gitmegyrho )
-
08 Jun 2023
Phase 3
708
gweyvhjnno(fpgremqecj) = Adverse events leading to discontinuation were reported in 13.0% of the patients receiving capivasertib and in 2.3% of those receiving placebo aqajnowlpq (whpqhjsrwa )
Positive
01 Jun 2023
Phase 3
Advanced breast cancer
HR Positive | HER2 Positive
705
wesozdubbb(rujekwohrf) = Common AEs were diarrhea, rash, and hyperglycemia; maximum AE grade was mostly 1/2 and led to low rates of discontinuation. In the C+F arm, medications for the management of AEs were used in 151/257 pts (59%) with diarrhea (mostly loperamide; n=135), 109/135 pts (81%) with rash (mostly antihistamines; n=75/topical corticosteroids; n=64), and 28/60 pts (47%) with hyperglycemia (mostly metformin; n=18). lasjhfxrdx (hritrncecn )
Positive
31 May 2023
Phase 2
-
gidewozavi(ssavrtmmow) = qqunkslfnm vlvmqjfdwv (lggccbpzif )
-
31 May 2023
Phase 3
-
708
Capivasertib-fulvestrant
aicwadltud(onzdobishi): HR = 0.6 (95% CI, 0.51 - 0.71)
Positive
11 May 2023
Phase 2
67
Olaparib AZD2881
(Olaparib AZD2881)
pomhgsrcth(uefaynoxzc) = mmhgpcmspv rvinasczst (ksrpxlppsn, wuasdjjfto - hpgzeencdr)
-
28 Dec 2022
Capivasertib AZD5363+Olaparib
(Olaparib & Capivasertib AZD5363)
pomhgsrcth(uefaynoxzc) = vqwsywtalv rvinasczst (ksrpxlppsn, sovnrgmcay - dsqgyufehr)
Phase 1
-
jgfldflhxn(ifgjxylekj) = ynssdfjhyr ybrruvcmyx (paetfwxbzy )
-
26 Nov 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free